GlassScriptPhysician profile
Matthew Wayne Hillegass
NPI 1346691813
$14,474.93
in general payments reported to CMS, 2019-2025
67 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $1,630 · 2021: $2,332 · 2022: $2,494 · 2023: $2,406 · 2024: $2,498 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,616.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,165.91 | 2019-2025 | |
| Novo Nordisk INC | $1,365.78 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,349.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,065.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $934.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $465.14 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $436.37 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $412.84 | 2019-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $381.15 | 2019-2025 | Verquvo, Vaxneuvance, Gardasil 9 |
| Amgen INC. | $367.26 | 2020-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $342.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.57 | 2019-2025 | Jardiance, Spiriva Respimat |
| Astellas Pharma US INC | $287.29 | 2021-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $265.67 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $259.79 | 2021-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $252.52 | 2020-2025 | Eliquis, Camzyos |
| Allergan, INC. | $239.14 | 2020-2021 | |
| Exact Sciences Corporation | $236.34 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.54 | 2020-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $219.19 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Boston Scientific Corporation | $214.59 | 2023-2025 | Watchman Flx, Watchman Access System |
| Daiichi Sankyo INC. | $167.40 | 2021-2023 | Injectafer |
| Corcept Therapeutics | $159.48 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $144.09 | 2023-2025 | Auvelity |
| Amneal Pharmaceuticals LLC | $142.79 | 2020-2021 | |
| Ardelyx, INC. | $130.86 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $123.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.71 | 2020-2023 | |
| Verona Pharma, INC. | $113.90 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $111.76 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.51 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $107.04 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $106.50 | 2020-2024 | Glassia |
| Janssen Pharmaceuticals, INC | $95.09 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $86.88 | 2024-2025 | Gemtesa |
| Mylan Specialty L.P. | $75.58 | 2021-2024 | Yupelri |
| Lundbeck LLC | $68.39 | 2020-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $68.32 | 2021 | |
| Tactile Systems Technology INC | $63.46 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Teva Pharmaceuticals USA, INC. | $57.52 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.56 | 2021-2024 | |
| Azurity Pharmaceuticals, INC. | $43.25 | 2022-2024 | Edarbi |
| Sanofi Pasteur INC. | $40.62 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $37.72 | 2020-2021 | |
| Ucb, INC. | $34.55 | 2021-2024 | Nayzilam |
| Tandem Diabetes Care, INC. | $34.53 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $29.86 | 2020 | |
| Philips North America LLC | $29.48 | 2022-2024 | (Ak6) Vest Therapy |
| Grt US Holding, INC. | $28.13 | 2021 | |
| Biogen, INC. | $27.15 | 2021-2022 | |
| Medtronic, INC. | $26.31 | 2023 | Minimed 630g, Intellis Adaptivestim |
| Ironwood Pharmaceuticals, INC | $24.87 | 2019-2020 | |
| Genentech USA, INC. | $24.81 | 2020 | |
| Paratek Pharmaceuticals, INC. | $23.34 | 2025 | Xhance, Nuzyra |
| Horizon Therapeutics Plc | $21.10 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.80 | 2024 | Lifevest |
| Grifols USA, LLC | $20.09 | 2022 | |
| Neurelis, INC. | $18.75 | 2023 | Valtoco |
| Exeltis, USA INC. | $18.23 | 2021 | |
| Sk Life Science, INC. | $14.49 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.48 | 2022 | |
| Nevro Corp. | $13.05 | 2023 | Senza |
| Alfasigma USA, INC. | $12.84 | 2020 | |
| Bardy Diagnostics, INC. | $12.00 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.87 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.62 | 2020 | |
| Medtronic USA, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hillegass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.